Patients With Renal Impairment Undergoing CT
Isovue and Visipaque in Renally Impaired Patients Undergoing CT
StatusCompleted No Results Posted
Indication/ConditionContrast Induced Nephropathy
The purpose of the study is to compare the incidence of contrast induced nephrotoxicity following the administration of Isovue or Visipaque in patients with mild to moderate renal impairment who undergo a clinically indicated IV contrast-enhanced (multidetector computed tomography) MDCT of the liver or MDCT angiography of the lower extremities. Serum Creatinine (SCr) will be measured before and up to 48-72 hours post dose.
Inclusion Criteria: referred for MDCT of liver or peripheral CTA stable baseline SCr of 1.5 - 2.5 mg/dL and/or calculated CrCl of 10-60 mL/min Exclusion Criteria: unstable renal function required prophylactic drugs to receive contrast (other than hydration) uncontrolled diabetes currently on dialysis